Brief: Lineage Announces Launch Of Phase 2A Study By Genentech Of Rg6501 (Opregen®) In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
28/11/2022 13:03
Nov 28 (Reuters) - Lineage Cell Therapeutics Inc
LCTX.A :
* LINEAGE ANNOUNCES LAUNCH OF PHASE 2A STUDY BY GENENTECH OF
RG6501 (OPREGEN®) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY
TO AGE-RELATED MACULAR DEGENERATION
Source text for Eikon: ID:nBw8LVqN5a
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million